Comparison of outcomes between sexes following percutaneous intervention for acute coronary syndrome
| . | Female . | Male . | P-value . |
|---|---|---|---|
| 30-day outcomes | n = 4931 | n = 16 045 | |
| Recurrent MI | 1.9% (94) | 1.7% (265) | 0.23 |
| Target vessel revascularization | 2.4% (119) | 2.5% (397) | 0.81 |
| Stroke | 0.7% (34) | 0.4% (57) | 0.002 |
| Rehospitalization | 16% (765) | 13% (2050) | <0.001 |
| MACCE | 4.1% (204) | 3.7% (600) | 0.20 |
| 12-month outcomes | n = 4117 | n = 13 107 | |
| Recurrent MI | 6.0% (246) | 4.7% (610) | 0.001 |
| Target vessel revascularization | 7.1% (293) | 7.2% (949) | 0.79 |
| Stroke | 1.5% (60) | 0.8% (101) | <0.001 |
| Rehospitalization | 41% (1642) | 34% (4418) | <0.001 |
| All-cause mortality | 2.6% (116) | 2.2% (317) | 0.11 |
| MACCE | 14% (570) | 12% (1561) | 0.001 |
| Long-term all-cause mortality | n = 4931 | n = 16 045 | |
| Median follow-up, years | 5 (2–8) | 5 (2–8) | 0.12 |
| Overall | 20% (951) | 13% (2095) | <0.001 |
| OMT, n = 13 395 | 17% (497) | 10% (1076) | <0.001 |
| NMT, n = 5639 | 22% (301) | 17% (710) | <0.001 |
| SMT, n = 1717 | 31% (153) | 25% (309) | 0.02 |
| . | Female . | Male . | P-value . |
|---|---|---|---|
| 30-day outcomes | n = 4931 | n = 16 045 | |
| Recurrent MI | 1.9% (94) | 1.7% (265) | 0.23 |
| Target vessel revascularization | 2.4% (119) | 2.5% (397) | 0.81 |
| Stroke | 0.7% (34) | 0.4% (57) | 0.002 |
| Rehospitalization | 16% (765) | 13% (2050) | <0.001 |
| MACCE | 4.1% (204) | 3.7% (600) | 0.20 |
| 12-month outcomes | n = 4117 | n = 13 107 | |
| Recurrent MI | 6.0% (246) | 4.7% (610) | 0.001 |
| Target vessel revascularization | 7.1% (293) | 7.2% (949) | 0.79 |
| Stroke | 1.5% (60) | 0.8% (101) | <0.001 |
| Rehospitalization | 41% (1642) | 34% (4418) | <0.001 |
| All-cause mortality | 2.6% (116) | 2.2% (317) | 0.11 |
| MACCE | 14% (570) | 12% (1561) | 0.001 |
| Long-term all-cause mortality | n = 4931 | n = 16 045 | |
| Median follow-up, years | 5 (2–8) | 5 (2–8) | 0.12 |
| Overall | 20% (951) | 13% (2095) | <0.001 |
| OMT, n = 13 395 | 17% (497) | 10% (1076) | <0.001 |
| NMT, n = 5639 | 22% (301) | 17% (710) | <0.001 |
| SMT, n = 1717 | 31% (153) | 25% (309) | 0.02 |
MACCE, major adverse cardiac and cerebrovascular events, included MI or stent thrombosis, target vessel revascularization and stroke, plus all-cause mortality at 12 months; MI, myocardial infarction; NDI, national death index; NMT, near optimal medical therapy, includes four guideline recommended medications; OMT, optimal medical therapy, includes five guideline recommended medications; SMT, suboptimal medical therapy, includes ≤3 guideline recommended medications.
Comparison of outcomes between sexes following percutaneous intervention for acute coronary syndrome
| . | Female . | Male . | P-value . |
|---|---|---|---|
| 30-day outcomes | n = 4931 | n = 16 045 | |
| Recurrent MI | 1.9% (94) | 1.7% (265) | 0.23 |
| Target vessel revascularization | 2.4% (119) | 2.5% (397) | 0.81 |
| Stroke | 0.7% (34) | 0.4% (57) | 0.002 |
| Rehospitalization | 16% (765) | 13% (2050) | <0.001 |
| MACCE | 4.1% (204) | 3.7% (600) | 0.20 |
| 12-month outcomes | n = 4117 | n = 13 107 | |
| Recurrent MI | 6.0% (246) | 4.7% (610) | 0.001 |
| Target vessel revascularization | 7.1% (293) | 7.2% (949) | 0.79 |
| Stroke | 1.5% (60) | 0.8% (101) | <0.001 |
| Rehospitalization | 41% (1642) | 34% (4418) | <0.001 |
| All-cause mortality | 2.6% (116) | 2.2% (317) | 0.11 |
| MACCE | 14% (570) | 12% (1561) | 0.001 |
| Long-term all-cause mortality | n = 4931 | n = 16 045 | |
| Median follow-up, years | 5 (2–8) | 5 (2–8) | 0.12 |
| Overall | 20% (951) | 13% (2095) | <0.001 |
| OMT, n = 13 395 | 17% (497) | 10% (1076) | <0.001 |
| NMT, n = 5639 | 22% (301) | 17% (710) | <0.001 |
| SMT, n = 1717 | 31% (153) | 25% (309) | 0.02 |
| . | Female . | Male . | P-value . |
|---|---|---|---|
| 30-day outcomes | n = 4931 | n = 16 045 | |
| Recurrent MI | 1.9% (94) | 1.7% (265) | 0.23 |
| Target vessel revascularization | 2.4% (119) | 2.5% (397) | 0.81 |
| Stroke | 0.7% (34) | 0.4% (57) | 0.002 |
| Rehospitalization | 16% (765) | 13% (2050) | <0.001 |
| MACCE | 4.1% (204) | 3.7% (600) | 0.20 |
| 12-month outcomes | n = 4117 | n = 13 107 | |
| Recurrent MI | 6.0% (246) | 4.7% (610) | 0.001 |
| Target vessel revascularization | 7.1% (293) | 7.2% (949) | 0.79 |
| Stroke | 1.5% (60) | 0.8% (101) | <0.001 |
| Rehospitalization | 41% (1642) | 34% (4418) | <0.001 |
| All-cause mortality | 2.6% (116) | 2.2% (317) | 0.11 |
| MACCE | 14% (570) | 12% (1561) | 0.001 |
| Long-term all-cause mortality | n = 4931 | n = 16 045 | |
| Median follow-up, years | 5 (2–8) | 5 (2–8) | 0.12 |
| Overall | 20% (951) | 13% (2095) | <0.001 |
| OMT, n = 13 395 | 17% (497) | 10% (1076) | <0.001 |
| NMT, n = 5639 | 22% (301) | 17% (710) | <0.001 |
| SMT, n = 1717 | 31% (153) | 25% (309) | 0.02 |
MACCE, major adverse cardiac and cerebrovascular events, included MI or stent thrombosis, target vessel revascularization and stroke, plus all-cause mortality at 12 months; MI, myocardial infarction; NDI, national death index; NMT, near optimal medical therapy, includes four guideline recommended medications; OMT, optimal medical therapy, includes five guideline recommended medications; SMT, suboptimal medical therapy, includes ≤3 guideline recommended medications.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
